Abstract It has been reported that cord blood transplantation (CBT) for patients with aggressive adult T-cell leukemia/lymphoma (ATL) results in poorer outcomes than transplantation using other stem cell sources. To identify a subset of ATL in which CBT is feasible, we retrospectively analyzed 27 patients treated with CBT at three institutions in Nagasaki Prefecture, Japan. The estimated overall survival (OS) rate at 3 years was 27.4 %. Of 16 patients who received CBT during remission (complete, CR, or partial, PR), the OS rate at 3 years was 50 %, while during refractory periods (non-CR or non-PR), the OS rate was 9.1 %. Reduced intensity conditioning (RIC) was given to 18 patients, and myeloablative conditioning (MAC) was used in nine, with 3-year OS of 50.0 and 0 %, respectively. Of the 19 deaths, nine were due to progressive disease, eight (five MAC and three RIC) to infection, and two to multiple organ failure. These results suggest that CBT provides similar results with those in other transplantation procedures for selected ATL patients, such as those in CR or PR. Further studies are needed to evaluate the use of CBT in aggressive ATL.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been applied as a curative option to patients with aggressive ATL [1, 2] . Several reports have demonstrated that allo-HSCT from related and unrelated peripheral blood (PB) or bone marrow (BM) is effective for ATL with a 3-year overall survival (OS) between 30 and 40 %, despite high transplant-related mortality (TRM) rate [3] [4] [5] [6] [7] [8] . It was also shown that allo-HSCT could provide long-term survival for some patients with aggressive ATL probably associated with graft-versus-lymphoma (GVL) effects [9] .
A recent nationwide retrospective study of allo-HSCT in 386 patients with ATL based on the registry data of the Japan Society for hematopoietic cell transplantation, the Japan Marrow Donor Program (JMDP) and the Japan Cord Blood Bank Network demonstrated that the 3-year OS of cord blood transplantation (CBT) is inferior to that of HLA-matched related and unrelated transplantation (17 vs 41 and 39 %, respectively), and CBT was one of the four recipient factors associated with lower survival rate [8] . The same group also reported the effect of graft-versushost disease (GVHD) and the intensity of conditioning regimen (reduced intensity conditioning, RIC, myeloablative conditioning, MAC) in allo-HSCT for ATL. They showed that grade I/II acute GVHD was associated with improved survival after allo-HSCT (including CBT) for ATL. The beneficial effect of mild acute GVHD was selected by multivariate analysis, suggesting that it would work in the setting of CBT as well [9] . Interestingly, the intensity of conditioning before transplantation did not have a significant impact on the overall survival for ATL patients who received allo-HSCT using BM or PB as stem cell sources [10] , although HSCT with RIC was significantly associated with ATL-related mortality.
Based on these reports, we thought that there might be a subset of ATL patients for which CBT could provide survival benefit, probably through graft-versus-ATL (GvATL) effect. To evaluate this possibility, we analyzed retrospectively our experiences of CBT for 27 ATL patients in the Nagasaki Transplantation Network. We could demonstrate that there were several long-term survivors after CBT, and that CBT might be an option for selected ATL patients such as those within clinical remission.
Patients and methods

Study design and data collection
Between October 2004 and July 2010, 27 patients with aggressive ATL underwent CBT using both myeloablative and reduced intensity conditioning at three institutions in Nagasaki prefecture. Data were collected and updated in September 2011. Three patients were included in a previous report of a nationwide retrospective study of the allo-HSCT for ATL by Hishizawa et al. [8] , and the data of two of these patients were updated. Before the transplantation procedure, all patients received conventional chemotherapy including anthracyclines. The median duration from diagnosis to transplantation was 114 days (range 56-481 days).
Transplantation
Of the 9 patients who received MAC, 3 received cyclophosphamide (CY; 60 mg/kg i.v. daily for 2 days) and busulfan (BU; 4 mg/kg p.o. or 3.2 mg/kg i.v. daily for 4 days), and 6 received CY and total body irradiation (TBI; total 12 Gy, 6 fractions) with or without cytarabine (2 g/m 2 i.v. for 4 days). All 18 patients except one in RIC group received fludarabine (FLU) and melphalan (MEL) with or without TBI regimen. 13 received FLU (25 mg/m 2 i.v. daily for 5 days), MEL (80 mg/m 2 i.v. for 1 day), and TBI (4 Gy), 4 received FLU and MEL, and 1 received FLU, BU (3.2 mg/kg i.v. daily for 2 days) and TBI (2 Gy). Prophylaxis against GVHD was as follows: tacrolimus (Tac), n = 12; Tac and methotrexate (MTX), n = 7; cyclosporine A (CyA) and MTX, n = 7; and CyA only, n = 1 ( Table 1) .
Statistical analysis and definition OS was measured from day 0 of transplantation until death from any cause or the last known follow-up. TRM was defined as all causes of non-relapse death after transplantation. Response was judged using Japan Clinical Oncology Group criteria for ATL as described [11, 12] . Survival curves were estimated using the Kaplan-Meier method.
Results
Patient characteristics
Clinical characteristics of the patients are summarized in Tables 1 and 2 . All patients had aggressive ATL (17 acute and 10 lymphoma). Median age was 52 (range 41-63) CR1 first complete remission, PR1 first partial remission, PR2 second partial remission, PIF primary induction failure, REL refractory after relapse, CY cyclophosphamide, BU busulfan, CA cytarabine, FLU fludarabine, MEL melphalan, TBI total body irradiation, CsA cyclosporine, TCR tacrolimus, sMTX short term methotrexate years. Sixteen patients showed a clinical response to prior chemotherapy [5 complete remission, 10 first partial remission (PR), and 1 s PR]. These patients were categorized as being ''chemosensitive'', while others were as ''refractory'' to chemotherapy. Number of chemosensitive patients was 4 and 12, and that of refractory patients was 5 and 6 in the MAC group and RIC group, respectively.
Engraftment
All patients received a cord blood cell infusion of over 2 9 10 7 /kg (median 2.75; range 2.00-4.28 9 10 7 /kg). All cord blood grafts, except one, were HLA-mismatched; 4 with one antigen mismatch, and 22 with two antigens. Two patients did not achieve engraftment because of early relapse, and three patients were not evaluable because of early treatment-related mortality before engraftment. A total of 22 patients achieved neutrophil regeneration, and the median number of days was 20 (range 13-98 days).
Overall outcome
The median survival time of all cases after transplantation was 192 days (range 6-2530 days), and the median observation time of the 8 surviving patients was 1079.5 days (range 666-2530 days) at the time of analysis (September 2011). The estimated OS rate at 3 years in all cases was 27.4 % after transplantation (Fig. 1) . The OS rate at 3 years in the chemosensitive group (CR and PR, 16 patients) and refractory group (primary induction failure and relapse, 11 patients) was 50.0 and 9.1 %, respectively, while that in the RIC group and MAC group was 50.0 and 0 %, respectively (Figs. 2, 3 ).
Cause of death
After transplantation, 19 patients died: 9 due to progressive disease (PD) and 10 due to TRM. Of the 10 TRM deaths, 8 were due to infection (5 bacterial, 2 adenovirus, and 1 cytomegalovirus pneumonia), and 2 were due to multiorgan failure (MOF). All 9 patients who received MAC died: 6 due to TRM (5 infections and 1 MOF) and 3 due to progressive disease. Of the 4 patients with chemosensitivity in the MAC group, 2 died due to PD and 2 to infection. Of the 18 patients who received RIC, 10 patients died. There were 6 deaths (5 PD and 1 MOF) among the 13 patients who received FLU, MEL, and TBI, 3 deaths (2 infections and 1 PD) among the 4 patients who received FLU and MEL, and 1 death (infection) of a patient who received FLU, BU, and TBI. Within 6 months after transplantation, there were 6 deaths (4 infections, 1 MOF and 1 PD) in patients who received MAC and 7 deaths (3 infections, 1 MOF and 3 PD) in patients who received RIC.
Graft-versus-host disease
A total of 8 patients developed acute GVHD at a median of 28 days (range 14-46 days): 3 with grade I, 4 with grade II, and 1 with grade IV. All four patients with grade II acute GVHD improved spontaneously. Only the grade IV patient received immunosuppressive treatment and improved. No GVHD was implicated in any deaths. Chronic GVHD was observed in 3 patients and was developed from acute GVHD: extensive type in 2 patients and limited type in 1. Among the 3 patients with chronic GVHD, 2 survived without relapse for 2.3 and 1.8 years. The other patient survived after relapse for 0.7 years and finally died due to PD.
Long-term survivors
Eleven patients survived more than 1 year (Table 2) . After transplantation, the median follow-up period was 2.3 years, and the longest follow-up period was 6.9 years. Eight and 3 patients were in chemosensitive and refractory group, respectively. Ten patients received RIC (9 with FLU, MEL, and TBI 4 Gy, and 1 with FLU and MEL), and only 1 patient received MAC. A total of 8 patients survived for a median of 3.0 (1.8-6.9) years. Of these 8 patients, 7 were in chemosensitive group and all received RIC. Three of 4 patients who survived more than 3 years were also in chemosensitive group. One patient who relapsed after 45 months transplantation achieved another CR by local radiation therapy and was alive 5 years after transplantation.
Discussion
Previous studies reported that there were no differences in the outcome after allo-HSCT using CB compared to that using HLA-matched [13] or HLA-mismatched [14] unrelated transplantation for adults with acute leukemia. ATL Fig. 3 Kaplan-Meier estimates of overall survival after cord blood transplantation according to conditioning type was not included in these studies; however, in a nationwide retrospective study of allo-HSCT for ATL in Japan, the 3-year OS rate after CBT of 17 % was significantly inferior to that of HLA-matched unrelated and mismatched related transplantation by 39 and 24 %, respectively [8] . The reasons for the poor outcome of CBT for ATL were considered to be high incidence of TRM, especially with fatal infectious complications [3] , which was related to the preexisting profound immunodeficiency of ATL [15, 16] .
The 3-year OS rate of CBT was 27.4 % in our study with several long-term survivors. Eight out of the 11 patients who survived more than 1 year showed chemosensitivity and received transplantation during CR or PR. This resulted in the difference of OS between chemosensitive (3-year OS, 50.0 %) and refractory (3-year OS, 9.1 %) patients (Fig. 2) . Considering that CBT during refractory status of ATL ended in poor outcome (5 cases of TRM, and 5 of PD), it suggested that CBT could provide reliable efficacy for limited ATL patients who were associated with chemosensitivity.
We also found that RIC showed better OS than MAC in our analysis (3-year OS of 50 and 0 %, respectively, Fig. 3 ). It has been reported that CBT after MAC is safe and effective treatment for adult patients with hematologic malignancies [17, 18] , which did not include ATL. In our analysis, 6 out of 9 patients who received MAC died with TRM, although there was no highly intensified conditioning regimen in MAC. The difference of TRM in the MAC group (6 of 9 patients) and RIC group (3 of 18 patients) seemed stem from the uneven distribution of chemosensitive patients; chemosensitive patients were biased in RIC group (12 out of 18, and 4 out of 9 in RIC and MAC, respectively). This is the limitation of our study with small number of cases to evaluate the relationship of the effect of chemosensitivity and conditioning regimen. A recent nationwide retrospective study of allogeneic bone marrow and peripheral blood stem cell transplantation for ATL in Japan with special emphasis on the effect of the preconditioning regimen revealed that TRM in MAC was higher than in RIC and that RIC was more significantly associated with ATL-related mortality than MAC, although no significant difference in OS between MAC and RIC recipients was observed [10] . RIC might provide long-term survival by reducing TRM.
It was previously reported that GvATL effect might affect long-term survival of patient with ATL after allo-HSCT from related marrow and peripheral blood and unrelated marrow donors [1, 3, 5] . Recent report by Kanda et al. [9] demonstrated that the development of mild-tomoderate acute GVHD confers a lower risk of disease progression and a beneficial influence on survival in allografted patients with ATL, which was in accordance with previous data [1, 3, 5] . In the present study, one patient who relapsed after CBT had achieved another CR only by local radiation therapy, and survived more than 2 years. With a suggestive anti-lymphoma effect after CBT for a patient with peripheral T-cell lymphoma and mycosis fungoides [19] , CvATL effect could also work after CBT for ATL.
Our results suggested that CBT could be feasible treatment for selected patients with ATL, probably those with chemosensitivity. Further clinical studies for the development of proper indication of CBT, an effective transplant procedure including a preconditioning regimen, are needed. For this purpose, a clinical trial of CBT with FLU, MEL, and TBI 4 Gy for chemosensitive ATL are underway in Japan.
